Onco Actu du 19 mars 2020

	4.1 DÉP., DIAG. & PRONO. - PROSTATE
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer [Myriad] Prolaris One of Only Two Prognostic Tests Recommended for Expanded Indications.
	4.11 DÉP., DIAG. & PRONO. - OVAIRE
New research shows which ovarian cancer patients won't benefit from immune-PARP combo [EurekAlert!] The study authors found that two factors - a specific pattern of gene mutations in the tumor cells and evidence of a vigorous immune response to the cancer - are markers of whether patients will respond to the combination therapy.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Researchers in Singapore find common therapeutic vulnerability for a genetically diverse and deadly leukaemia [Duke] “Our discovery is like finding the ‘one ring that rules them all’. Since there are many cancer-causing genetic mutations that occur when chronic phase CML transforms to blast crisis, it has been very challenging to determine which ones are critical to BC, and therefore important to target."
	5.10 TRAITEMENTS - ESSAIS
In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1 [NCI] Results of the trial were published March 18, 2020, in the New England Journal of Medicine.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Bristol Myers' Juno unit enlists Oxford BioMedica for CAR-T work [Fierce Pharma] Under the deal, Juno gets access to Oxford BioMedica’s newest commercial manufacturing center, OxBox. The site, set to start operating this year, boasts six GMP clean room suites, warehousing, cold chain facilities and additional labs.
	5.2.6 PHARMA - BIOTECH
Ex-Shire cancer leader raises cash for solid tumor research [Fierce Biotech] The team’s interest in oxMIF is underpinned by the target’s presence in multiple solid tumor types and absence from healthy tissues.
Former Shire execs set up shop to take a shot at 'under the radar' cancer target [EndPoints] Macrophage migration inhibitory factor, or MIF, is a cytokine ubiquitous across the human body. The company is targeting a disease-related isoform of MIF, called oxMIF.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
As Covid-19 R&D goes into overdrive, nuts-and-bolts biopharma research is hitting the skids. How bad is it? [EndPoints] Addex’s reasons for the delay leave little doubt that unless you’re working on Covid-19, the biopharma world is experiencing a punishing slowdown — if not collapse — of basic trial activities.